Tempus, a technology company focused on helping doctors personalize cancer treatment by collecting, sorting and analyzing clinical and molecular data, has announced a new collaboration with cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania to improve and personalize...
Tempus, a technology company that enables physicians to deliver personalized cancer care, has hired Erik Phelps to serve as Executive Vice President and General Counsel. Phelps will be responsible for a broad range of legal areas for the company, including general corporate matters and strategy. Prior to joining...
Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, announced that it will work with Duke University School of Medicine on an initiative to accelerate research and treatment for brain cancer. Scientists at the Preston Robert Tisch...
Tempus, a technology company focused on helping doctors personalize cancer care, and University Hospitals Seidman Cancer Center have joined together to improve research and healthcare by making genomic data, advanced molecular analysis and clinical decision support tools available to the hospital's researchers, physicians and healthcare providers.As part...
Tempus, a technology company that helps physicians deliver customized cancer care, has selected Dr. Gary Palmer to serve as the company's Chief Medical Officer. Palmer will be responsible for leading clinical activities for the company and supporting external collaborations and strategic partnerships. "Gary has spent the last 20 years...
Tempus, a technology company focused on helping doctors personalize cancer care, and Rush University Medical Center announced today a partnership to pursue their shared goal of providing customized treatment to cancer patients."Technology has come a long way since the human genome was first mapped more than...
Tempus, a health-tech company focused on personalizing cancer care, and the University of Michigan Comprehensive Cancer Center have partnered to bring MI-ONCOSEQ to patients and health care providers across the country who are seeking the high quality data and analyses necessary to personalize treatment for their patients.The M...
Tempus, a health-tech company that enables physicians to deliver personalized cancer care through its interactive analytical and machine learning platform, announced today that it was selected by the Pancreatic Cancer Action Network to serve as a partner in its Precision Promise initiative, the first large-scale precision medicine trial...
Tempus will provide genomic sequencing and analysis for Lurie Cancer Center OncoSET, Northwestern’s precision medicine initiative designed to provide personalized care and customized treatment for cancer patients.Tempus, a health-tech company focused on helping doctors personalize cancer care, and the Robert H. Lurie Comprehensive Cancer Cen...
Tempus is pleased to announce the opening of the Tempus Lab, a highly robotic laboratory optimized for high-throughput clinical next-generation sequencing with a capacity of 52,000 samples annually. “As a scientist, producing high-quality, trustworthy data is critical,” said Sam Bettis, Director of Laboratory Operations at Tempus. “Tempus has invested...